Hosted on MSN1mon
Sage confirms Biogen’s bid to acquire remaining stakeBiogen currently owns a 10.2% stake in SAGE, and its offer price implies a ~30% premium to the company’s closing price on Friday. More on Biogen, Sage Therapeutics, etc. Biogen Holds On, But ...
EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...
Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results